Cytodyn Inc (CYDY)

[Borel Fields]

OK - Everyone else has complained. Here's how the PR should have been written - IM(not so)HO. Excuse table formatting.

Leronlimab in COVID: Sixty percent reductions in Severe Adverse Event ("SAE") safety metrics in controlled trial. Efficacy data upcoming.

----

In an 86-patient randomized controlled trial, leromlimab reduced the percentage of patients with SAEs by 58.4% and the total number of SAEs per patient by 63.8%. Considering any level of adverse event, leronlimab decreased patients impacted by 32.2%.

The percentage of leronlimab patients with SAEs was 8.9%, versus 21.4% in the control arm of the trial. The control arm received "standard of care" treatment, which typically included multiple other drugs.

Because the definition of Serious Adverse Events includes both disease-caused and drug-caused events, they provide possible insight into the more detailed clinical efficacy findings that will be released as available. No drug-caused SAEs were recorded among leronlimab users.

Raw numbers are as follows:

Totals.-----------------.Leronlimab.---.Control
Number of patients.--------- 56 --------- 28
# patients with SAEs.------- 05 --------- 06
Total SAEs.------------------- 08 --------- 11
# patients, any AE.--------- 19 --------- 14

Per patient - - - - - - - Leronlimab - - Control - -Relative Risk
% patients with SAEs - - - - 8.9% - - - - 21.4% - - - -58.4%
Total SAEs per patient - - - .142 - - - - .392 - - - - -63.8%
% patients with any AE - - - 33.9% - - - 50.0% - - - - -32.2%